Saturday, August 29th 

5:45 -  6:00           Welcome, clarifications and announcements  (D.  Sharon, A. OBryan)

Session 1. RLS basic science session (chair: A. Salminen, Germany) 

6:00 – 6:15   An Update on the Genetics of RLS (B. Schormair, Germany)

6:15 – 6:30     Genetic characterization of RLS in Québec  (F. Akcimen,  Canada) 

6:30 – 6:45     Probing the relationship between BTBD9 and MEIS1 in animal models of RLS (Y. Li, USA)

6:45 – 7:00     Sleep-related muscle activity is augmented by administration of serum from RLS patients in Btbd9 mutant mice. 
    (S. Chikahisa, Japan)

7:00 - 7:15      PTPRD: Drugging a novel RLS target (G.Uhl, USA)

Session 2. New developments in iron measurement and treatment in RLS (chair: C.J. Earley USA)

7:15  – 7:30 Iron regulation, iron status and relevance to iron treatment (C. J. Earley, USA)  

7:30 – 7:45     The clinical implementation of the quantitative transcranial sonography (Celia Garcia Malo, Spain)

7:45  – 7:57    Intravenous Iron protocol for adolescents (D. Picchietti, USA)

7:57 – 8:15     Intravenous Ferric Carboxymaltose in children, a single center experience (L. DelRosso, USA)

Session 3. Young investigators (chair: R. Zak / A.S. Walters , USA)

8:15 – 8:30  RLS-associated risk variant affects MEIS1 expression during neural development (A. Nikolic, Germany)

8:30 – 8:45  A genetic and transcriptome-wide study for restless legs syndrome (F. Akcimen, Canada)

8:45 – 9:00  Sleep-related leg movements in obstructive sleep apnea: definitions, determinants, and clinical consequences
(M. Schipper, Netherlands)

9:00 – 9:15  Rethinking bedtime resistance in children with autism: Is restless legs syndrome to blame? (M. Kanney, USA)

9:15 – 9:30  Prevalence and impact of restless legs in patients with myasthenia gravis (M. AlGaeed, USA)

9:30 – 10:00 Discussion, more Q&A, networking, feedback

 Sunday, August 30th 

Session 4. RLS and PLMS: clinical aspects and treatment (chair: D. Sharon, USA)

6:00 – 6:20 RLS and PLMS: pathogenesis and the adenosine hypothesis (S. Ferre, USA) 

6:20 – 6:45 Testing the adenosine hypothesis:  a double-blind, cross-over, placebo-controlled trial with
dipyridamole  (D. Garcia-Borreguero, Spain)

6:45 – 7:00  Dopaminergic treatment modulates functional brain connectivity in RLS (A. Stefani, Austria)

7:00 – 7:15 Nearly 25% of RLS Patients Nationally Treated With Dopamine Agonists Are Taking Higher Doses Than The Maximum       Recommended By FDA And Expert Guidelines. (J. Winkelman, USA)

7:15 – 7:30 Update on Painful Willis-Ekbom disease: an unbearable and distinct form of restless legs? (E. Karroum, USA)   

7:30 – 7:45 Epidural electric spinal stimulation in a severe case of RLS/PLM  (M. Manconi, Switzerland)

7:45 – 8:00     Discussion, more Q&A, networking

Session 5. Cooperative and IRLSSG endorsed projects (chair: J. Winkelman, USA)

8:00 – 8:20  Introduction to EURLSSG and Highlights from the EURLSSG meeting (R. Silvestri, Italy)

8:20 – 8:30  RLS projects by RLS foundation (K. Dzienkowski, USA) 

8:30 – 8:40  A Call to Arms--breaking down silos and increasing interagency cooperation (R. Zak, USA)

8:40 – 8:55  Q&A session on endorsed IRLSSG projects:

1. Experimental Readouts of Animal Models of Restless Legs Syndrome: Consensus Guidelines (A. Salminen, Germany)
2. Diagnostic accuracy of RLS tools (J Winkelman, S. Fulda, Switzerland)  
3. Opioid registry update (J. Winkelman, USA)
4. RSD project (L. DelRosso, USA)
5. Pediatric Task force (Art Walters, USA)
6. Update on AASM TF on Guidelines for treating RLS (A. Walters, USA)

8:55 – 9:05 Year in review  and future projects discussion (J Winkelman, USA)

9:05-9:30 Business meeting